Statins are lipid regulators that inhibit the rate-limiting enzyme in the early stages of cholesterol synthesis in the body, accelerating the removal of very-low-density lipoprotein remnants (intermediate-density lipoproteins) and low-density lipoproteins and small, dense low-density lipoproteins from circulating blood; and inhibiting the synthesis of very-low-density lipoproteins in the liver. This type of drug lowers cholesterol and LDL cholesterol significantly, but also lowers triglycerides, celiac particles, and raises HDL cholesterol. In addition to lipid regulation, statins have other effects: anti-inflammatory, antioxidant, antiplatelet aggregation, antithrombotic effect; improve the function of the vascular endothelium; inhibit the proliferation of smooth muscle cells and matrix. Therefore, they can prevent, slow down, stabilize and abate atherosclerotic damage, as well as prevent and improve myocardial ischemia, inhibit myocardial hypertrophy and fibrosis, and antiarrhythmic effects. These drugs are suitable for patients with hypercholesterolemia, mixed hyperlipidemia with predominantly elevated cholesterol, atherosclerosis and coronary heart disease. Common adverse effects of statin lipid regulators include gastrointestinal disturbances (nausea, bloating), rash, insomnia, and less commonly include elevated transaminases (2%), myopathy (1/1000), and rhabdomyolysis (1-2/100,000). During the drug should pay attention to the symptoms of hidden pain in the liver area and regular checks of liver function, such as alachlor aminotransferase/glutamine aminotransferase elevation does not exceed 3 times the normal value can continue to use the drug or reduce the dosage, but to monitor the liver function; such as more than 3 times the lipotropic drugs suspension of the drug, plus liver-protecting drugs treatment. Statin lipid regulating drugs serious adverse reactions have myopathy, which is caused by rhabdomyolysis, clinical manifestations can be muscle weakness, myalgia, myalgia, fatigue, fever, etc., phosphocreatine kinase is elevated, greater than the upper limit of normal 10 times. The above symptoms should be noted during drug administration, and the drug should be discontinued if the blood phosphocreatine kinase is elevated more than 5 times the normal value. If there is sepsis, major surgery or trauma, hypotension and other conditions that cause myolysis during the period of administration, the drug should be suspended. Check liver function, creatinine, phosphocreatine kinase and blood lipids 4-8 weeks after the first dose. Review the above indexes every 3-6 months thereafter; review every 6-12 months after reaching the standard.